Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation.
Table 2 summarizes the recommendations regarding the use of cardiovascular drugs during pregnancy and lactation.
Qasqas
Shadi A
SA
Departments of Medicine, Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, USA.
McPherson
Camille
C
Frishman
William H
WH
Elkayam
Uri
U
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008429:Maternal Welfare; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011247:Pregnancy / Q000187:drug effects*
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors